A detailed history of Sectoral Asset Management Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Sectoral Asset Management Inc holds 3,815 shares of HALO stock, worth $217,111. This represents 0.1% of its overall portfolio holdings.

Number of Shares
3,815
Previous 5,680 32.83%
Holding current value
$217,111
Previous $231,000 13.85%
% of portfolio
0.1%
Previous 0.11%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$37.81 - $52.4 $70,515 - $97,726
-1,865 Reduced 32.83%
3,815 $199,000
Q1 2024

May 14, 2024

SELL
$33.68 - $41.95 $11,788 - $14,682
-350 Reduced 5.8%
5,680 $231,000
Q4 2023

Feb 14, 2024

SELL
$33.32 - $42.1 $4.66 Million - $5.89 Million
-139,970 Reduced 95.87%
6,030 $222,000
Q3 2023

Nov 14, 2023

BUY
$36.46 - $44.03 $239,286 - $288,968
6,563 Added 4.71%
146,000 $5.58 Million
Q2 2023

Aug 11, 2023

BUY
$30.28 - $38.74 $667,280 - $853,713
22,037 Added 18.77%
139,437 $5.03 Million
Q1 2023

May 12, 2023

SELL
$32.86 - $55.7 $657,200 - $1.11 Million
-20,000 Reduced 14.56%
117,400 $4.48 Million
Q3 2022

Nov 10, 2022

BUY
$38.53 - $51.78 $269,710 - $362,460
7,000 Added 5.37%
137,400 $5.43 Million
Q2 2022

Aug 15, 2022

BUY
$37.35 - $48.3 $164,340 - $212,520
4,400 Added 3.49%
130,400 $5.74 Million
Q1 2022

May 10, 2022

BUY
$31.97 - $41.06 $4.03 Million - $5.17 Million
126,000 New
126,000 $5.03 Million
Q3 2020

Nov 13, 2020

SELL
$25.74 - $29.63 $535,392 - $616,304
-20,800 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$16.25 - $26.81 $338,000 - $557,648
20,800 New
20,800 $558,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.93B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Sectoral Asset Management Inc Portfolio

Follow Sectoral Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Sectoral Asset Management Inc with notifications on news.